Pharma BD Deal Intelligence
A $6B global collaboration that gave AstraZeneca co-development rights to Daiichi Sankyo's TROP2-directed ADC datopotamab deruxtecan, structured as $1B staged upfront plus up to $5B in milestones—AZ's second major ADC bet on Daiichi following the 2019 Enhertu deal.
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate. AstraZeneca will pay $1 billion upfront in staged…
AstraZeneca and Daiichi Sankyo expanded their collaboration with a deal worth up to $6 billion for datopotamab deruxtecan, a TROP2-targeting ADC for lung and…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca and Daiichi Sankyo entered a global collaboration to jointly develop and commercialize datopotamab deruxtecan (DS-1062), a TROP2-directed antibody-drug conjugate. AstraZeneca paid $1 billion upfront in staged payments ($350M at execution, $325M at 12 months, $325M at 24 months) with up to $5 billion in regulatory and sales milestones. This was the second major AZ-Daiichi ADC collaboration following the 2019 Enhertu deal. Daiichi Sankyo retained exclusive rights in Japan.
HR+/HER2- breast cancer is the largest breast cancer segment (~70% of cases) and dato-DXd (TROP2 ADC) competes across multiple MOA lines. Endocrine therapy + CDK4/6 inhibitors (1L standard): palbociclib (Ibrance, Pfizer, ~$4.7B 2023), ribociclib (Kisqali, Novartis, ~$2.1B 2023), and abemaciclib (Verzenio, Lilly, ~$3.9B 2023) combined with aromatase inhibitors or fulvestrant. PI3K/AKT inhibitors: alpelisib (Piqray, Novartis) for PIK3CA-mutant; capivasertib (Truqap, AstraZeneca) approved November 2023 for PIK3CA/AKT1/PTEN-altered post-endocrine. Selective estrogen receptor degraders (SERDs): elacestrant (Orserdu, Menarini/Stemline) approved January 2023 for ESR1-mutant advanced disease post-endocrine. TROP2 ADC (direct class): sacituzumab govitecan (Trodelvy, Gilead; approved HR+/HER2- post-endocrine February 2023 based on TROPiCS-02, ~$1.1B 2023 across all indications). HER2-low ADC: trastuzumab deruxtecan (Enhertu, AZ/Daiichi; DESTINY-Breast04 approval August 2022 for HER2-low metastatic, DESTINY-Breast06 approval 2024 for HER2-ultralow) disrupted the HR+/HER2-low subset. Chemotherapy (later lines): capecitabine, eribulin (Halaven, Eisai), vinorelbine. For AstraZeneca/Daiichi, dato-DXd's TROPION-Breast01 showed PFS benefit vs. chemo leading to January 2025 FDA approval in pretreated HR+/HER2- disease; the commercial positioning question is head-to-head vs. Trodelvy, and the HR+/HER2-low subset is also partially captured by the partner asset Enhertu - creating intra-portfolio cannibalization risk.
NSCLC is Dato-DXd's most strategically important indication given the size of the previously-treated non-squamous market. Anti-PD-1/PD-L1 (1L backbone): pembrolizumab (Keytruda, Merck, ~$25B 2023), nivolumab (Opdivo, BMS), atezolizumab (Tecentriq, Roche), durvalumab (Imfinzi, AstraZeneca), and cemiplimab (Libtayo, Regeneron). TROP2 ADC (direct class rival): sacituzumab govitecan (Trodelvy, Gilead) ran EVOKE-01 in NSCLC but missed primary OS endpoint (January 2024), reducing direct-class threat. HER3 ADC (AZ partner asset and class rival): patritumab deruxtecan (HER3-DXd, Merck/Daiichi Sankyo) received priority review then CRL 2024; still in development. HER2 ADC: trastuzumab deruxtecan (Enhertu, AZ/Daiichi) approved for HER2-mutant NSCLC August 2022. EGFR-targeted: osimertinib (Tagrisso, AZ, ~$5.8B 2023) for EGFR-mutant. KRAS G12C: sotorasib (Lumakras, Amgen), adagrasib (Krazati, BMS/Mirati). Chemotherapy (docetaxel+/-ramucirumab, pemetrexed) remains 2L+ standard. Dato-DXd's TROPION-Lung01 showed modest PFS benefit in previously-treated non-squamous NSCLC, leading to FDA BLA filing and January 2025 accelerated approval in EGFR-mutant post-TKI subset only. The commercial threat is primarily to docetaxel and potentially Trodelvy (following its OS miss), with positioning as post-chemo, post-IO TROP2-enriched.
Triple-negative breast cancer (TNBC) is an aggressive subset (~15% of breast cancer) with a defined ADC and checkpoint inhibitor standard of care. TROP2 ADCs (direct class): sacituzumab govitecan (Trodelvy, Gilead, ~$1.1B 2023 across all indications) is FDA-approved for 2L+ metastatic TNBC based on ASCENT (NEJM 2021); dato-DXd (AstraZeneca/Daiichi) competes directly and TROPION-Breast02 in TNBC is a pivotal readout. Anti-PD-1/PD-L1: pembrolizumab (Keytruda, Merck) + chemo is approved for PD-L1+ 1L metastatic TNBC (KEYNOTE-355) and for high-risk early TNBC perioperative (KEYNOTE-522); atezolizumab (Tecentriq, Roche) had its TNBC indication withdrawn. PARP inhibitors: olaparib (Lynparza, AZ/Merck) and talazoparib (Talzenna, Pfizer) for gBRCA-mutant TNBC. HER2-low ADC: trastuzumab deruxtecan (Enhertu, AZ/Daiichi) in HER2-low TNBC (DESTINY-Breast06 extension). Chemotherapy: capecitabine, eribulin (Halaven, Eisai), gemcitabine/carboplatin, taxanes. For AstraZeneca/Daiichi, dato-DXd enters a market where Trodelvy has 3 years of commercial lead; differentiation requires a cleaner tolerability profile or demonstrated advantage in TROP2-low/-medium subsets. The combination strategy (dato-DXd + durvalumab) is being explored in TROPION-Breast04 for 1L TNBC.
AstraZeneca and Daiichi Sankyo signed $6B collaboration for datopotamab deruxtecan (Dato-DXd) TROP2 ADC.
Partners withdrew broad NSCLC BLA and refiled focusing on EGFR-mutated NSCLC after TROPION-Lung01 missed OS significance.
Dato-DXd granted BTD for previously treated EGFR-mutated NSCLC patients. Regulatory step in AstraZeneca PLC's acquisition process for Daiichi Sankyo Co. Ltd..
Datopotamab deruxtecan approved in US and Japan for breast cancer indication. Regulatory step in AstraZeneca PLC's acquisition process for Daiichi Sankyo Co. Ltd..
Regulatory Setback but Advancing. Assessment of AstraZeneca PLC's $6B acquisition of Daiichi Sankyo Co. Ltd. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Daiichi Sankyo Company, Limited (this deal) | 2020 | $6.0B | 62 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2020 deals · AstraZeneca PLC deals · Oncology deals